Compare Corning Incorporated (GLW) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs Travere Therapeutics Inc. Common Stock — how do they compare? Corning Incorporated trades at $135.89 (market cap $127.95B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Corning Incorporated is far larger — about 26.2× Travere Therapeutics Inc. Common Stock's market cap, and Corning Incorporated pays a 0.75% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Corning Incorporated for 36 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| GLW | TVTX | |
|---|---|---|
Market Cap | $127.95B | $4.88B |
Volume | 7,325,250 | 1,668,577 |
Sector | Technology | Health |
52-Week High | $255.79 | $67.52 |
52-Week Low | $78.03 | $26.79 |
Typical Hold Time | 36 Days | 0 Days |
Enterprise Value | $134.83B | $5.01B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corning (GLW) trades at $148.52, up 0.87% with recent earnings beats and a major $3B AT&T fiber deal driving optimism. Technical indicators show bearish momentum with support at $144 and resistance at $153. The company demonstrates strong fundamental improvement with 2025 revenue reaching $15.63B and net income surging to $1.60B, though valuation multiples remain elevated with a P/E of 68.45.
GLW presents growth potential through AI infrastructure demand and fiber expansion, supported by 57% analyst buy ratings and a $171.25 price target. Key risks include patent litigation investigations and high valuation sensitivity to earnings growth. The stock offers 15% upside to consensus target but requires monitoring of legal developments and margin sustainability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
